Avadel Pharmaceuticals Q1 2024 GAAP EPS $(0.30) Misses $(0.21) Estimate, Revenue $0
Portfolio Pulse from Benzinga Newsdesk
Avadel Pharmaceuticals reported a Q1 2024 GAAP EPS loss of $(0.30), missing the $(0.21) estimate, marking a 42.86% miss but a 37.5% improvement over last year's $(0.48) per share loss. The company's revenue for the quarter was $0.
May 08, 2024 | 11:08 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Avadel Pharmaceuticals reported a larger than expected Q1 2024 loss of $(0.30) per share compared to the $(0.21) estimate, showing improvement from last year's $(0.48) loss. Revenue was reported as $0.
Missing the EPS estimate by 42.86% is likely to negatively impact investor sentiment in the short term, despite the year-over-year improvement in losses. The reported revenue of $0 could further concern investors about the company's growth prospects and financial health.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100